Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.
- Published In:
- Diabetes care, 48(9), 1607-1611 (2025)
- Authors:
- Eldor, Roy, Avraham, Noa, Rosenberg, Orit, Shpigelman, Miriam, Golan-Cohen, Avivit, Cukierman-Yaffe, Tali, Merzon, Eugene, Buch, Assaf
- Database ID:
- RPEP-10835
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10835APA
Eldor, Roy; Avraham, Noa; Rosenberg, Orit; Shpigelman, Miriam; Golan-Cohen, Avivit; Cukierman-Yaffe, Tali; Merzon, Eugene; Buch, Assaf. (2025). Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.. Diabetes care, 48(9), 1607-1611. https://doi.org/10.2337/dc25-0690
MLA
Eldor, Roy, et al. "Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.." Diabetes care, 2025. https://doi.org/10.2337/dc25-0690
RethinkPeptides
RethinkPeptides Research Database. "Gradual Titration of Semaglutide Results in Better Treatment..." RPEP-10835. Retrieved from https://rethinkpeptides.com/research/eldor-2025-gradual-titration-of-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.